What the Research Actually Shows About CJC-1295 vs Sermorelin

CJC-1295 and sermorelin are both GHRH-receptor agonists studied for growth hormone release. They differ in how long the signal lasts and in the quality of the human evidence behind each. This comparison sets out what the primary literature reports for each compound, where the two are routinely confused, and which questions the record cannot answer.

Which is better, CJC-1295 or sermorelin?

Both peptides are analogues of growth hormone releasing hormone. Both act on GHRH receptors in the pituitary. Sermorelin is the native human GHRH(1-29) fragment and clears within minutes. CJC-1295 is an engineered version built to survive far longer in plasma.

That duration gap is the whole comparison. Everything else that gets argued about sits downstream of it, and most of that argument is inference.

Sermorelin vs CJC-1295 at a glance

Every figure above comes from the primary paper cited, never from a secondary summary.

What does CJC-1295 mean on a label?

Two very different molecules get sold under one name. Sorting them out is the single most useful thing a reader can take from this page.

CJC-1295 with DAC carries a Drug Affinity Complex. A maleimidopropionamide group conjugates the peptide to the free thiol on Cys34 of serum albumin (PMID 15817669). Once bound, the molecule circulates attached to albumin, and FDA gives the DAC free base a molecular weight of 3647.95 g/mol. That conjugation is the reason its half-life runs in days.

CJC-1295 no DAC carries no such group, and its proper name is modified GRF(1-29). A 2026 review in Frontiers in Endocrinology treats the two as separate entities throughout, which is the correct handling (PMID 42395176).

The practical consequence of mixing them up is large. Teichman and colleagues studied the with-DAC form. Pages quoting that half-life beside a no-DAC product attach days-long kinetics to a molecule nobody measured that way. This single conflation corrupts most comparisons available online. For the two forms separately, see our CJC-1295 with DAC monograph and our modified GRF(1-29) page.

How do CJC-1295 and sermorelin differ at the receptor?

Both compounds bind GHRH receptors on pituitary somatotrophs. Neither one opens a new pathway that native GHRH does not already use. The pituitary responds as it responds to its own releasing hormone, and downstream somatostatin feedback still applies in both cases.

These compounds are often filed alongside GHRPs such as ipamorelin. Sorting them into one bucket is a category error worth correcting. GHRPs act on the ghrelin receptor, a separate target with separate kinetics and a separate literature. We cover the distinction in GHRH analogues vs GHRPs.

So the useful question is not which compound is stronger at the receptor. It is how long each one keeps that receptor occupied, and what a pituitary does when the incoming signal stops resembling a pulse. Native GHRH arrives in bursts, and a molecule with a multi-day half-life does not.

What does the sermorelin evidence show?

Sermorelin is GHRH(1-29)-NH2, the shortest fragment of native GHRH that retains biological activity. In plasma it is cleaved rapidly by dipeptidyl peptidase IV, which cuts between residues 2 and 3 (PMID 7937325). Clearance happens fast, and the resulting GH response is correspondingly brief.

The registration-era evidence came from pediatric growth hormone deficiency. One multicenter study enrolled 110 previously untreated prepubertal study subjects. Mean height velocity rose from 4.1 cm per year at baseline to 8.0 cm per year at six months. It then settled back to 7.2 cm per year at twelve months (PMID 8772599). About 74% were rated good responders at the six-month mark. Bone age advanced roughly in step with height age, and investigators reported no excessive IGF-1 generation.

Three further findings from that era rarely appear on comparison pages, and each one matters.

Sermorelin underperformed growth hormone itself

One randomized three-arm study measured both. Mean height velocities reached 9.2 and 9.3 cm per year on GHRH(1-29)-NH2, against 14.6 cm per year on GH (PMID 8329830). A second randomized study reached a similar conclusion about relative effect (PMID 8329826).

Antibodies developed in nearly every treated subject

In that same trial, 39 of 40 study subjects on GHRH(1-29)-NH2 developed GHRH antibodies, which had almost disappeared nine months after treatment stopped (PMID 8329830). Investigators found no correlation between antibody titre and height gain.

The response faded across months

Those assessed with 24-hour GH profiling showed a biphasic pattern, with integrated GH rising early and then falling by three and six months (PMID 8329829). The authors raised desensitization of pituitary GHRH receptors as one candidate explanation, alongside antibodies and somatostatin changes.

The common claim that sermorelin preserves the feedback loop is a fair reading of the no-excessive-IGF-1 finding. It is not a finding of durable effect, and those are separate questions. Our sermorelin monograph sets out the full record.

What does the CJC-1295 evidence show?

CJC-1295 is a deliberately engineered molecule. Its design logic comes from GRF analogue chemistry worked out in the 1990s, which targeted four positions for four separate reasons (PMID 7937325). Substitution at position 2 blocks DPP-IV cleavage, and substitution at position 8 reduces chemical isomerization. Position 27 was altered to prevent oxidation of a methionine residue. The position 15 change is less settled. Campbell and colleagues describe that change as previously demonstrated to enhance receptor binding affinity. FDA's own review of the molecule records no rationale for it. The DAC group was then added on top of that stabilized backbone.

The human dataset amounts to a single paper. Teichman and colleagues ran two randomized, placebo-controlled, double-blind ascending-dose trials in healthy adults aged 21 to 61, lasting 28 and 49 days (PMID 16352683). Their reported findings, exactly as published:

• Mean plasma GH rose 2 to 10 fold, dose-dependently, for six days or more after one administration.
• Mean plasma IGF-1 rose 1.5 to 3 fold, for nine to eleven days.
• The estimated half-life of CJC-1295 was 5.8 to 8.1 days.
• After multiple administrations, mean IGF-1 stayed above baseline for up to 28 days.
• No serious adverse reactions were reported.

Competitor pages quote these as conflicting numbers, offering 1.5 to 3x on one site and 2 to 10x on another. Both figures are correct, and the two do not contradict each other at all. They report two entirely different endpoints from the same trial. The 2 to 10 fold figure describes growth hormone, and the 1.5 to 3 fold figure describes IGF-1. Any page presenting them as rival estimates of one quantity has not read the paper.

Development stopped not long after that trial. ConjuChem withdrew CJC-1295 with DAC from clinical trials in 2006, following the death of a participant in a Phase II study. The data from that trial were never published.

Every figure above belongs to the with-DAC form. None of it has been demonstrated for modified GRF(1-29) in a published human trial.

What is the regulatory status of each in 2026?

Law, agency policy, and commentary get blended constantly on this topic. They are separate things, and this section keeps them separate.

Sermorelin has a genuine approval history. It was approved in 1997 under the brand name Geref for pediatric growth hormone deficiency. EMD Serono discontinued the product in 2008 for commercial reasons, and the applications were withdrawn in 2009. FDA later determined the product had not been withdrawn for reasons of safety or effectiveness. Sermorelin was not among the peptides placed in Category 2 of the interim 503A bulks list in September 2023.

CJC-1295 holds no approval that regulators have identified. FDA surveyed twelve countries, among them Australia, Canada, Japan and the United Kingdom, plus the European Union. It found no approved product containing any form of CJC-1295 in any of them. No registration-track development program appears in the public record either.

The compounding history runs on its own track. CJC-1295 was placed in Category 2 of the interim 503A bulks list in September 2023. Its nominators later withdrew the nomination, and it was removed from Category 2 effective 27 September 2024. In April 2026 FDA moved it to the withdrawn-nominations table. FDA nonetheless brought five CJC-1295 forms before the Pharmacy Compounding Advisory Committee on 4 December 2024. It proposed that none of them be added to the bulks list. Committee votes are advisory, and no final rule has published.

The July 2026 PCAC claim is wrong

Many comparison pages describe a July 2026 PCAC vote that assigned these two compounds to opposing categories. That vote never took place at all. The Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 and reviewed seven peptides: BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon, and emideltide. Neither CJC-1295 nor sermorelin appeared on that docket. Our explainer on the July 2026 PCAC vote covers what the committee actually decided.

One rule explains most of the resulting confusion. Removal from Category 2 does not place a substance in Category 1. Category 1 is an interim enforcement-discretion policy covering substances still under evaluation, while Category 2 flags substances FDA identified as raising significant safety concerns. A substance sitting in the withdrawn-nominations table falls outside both. Commercial sources claiming a clean Category 1 versus Category 2 split between these two compounds contradict each other. No primary record supporting that claim was found for either one.

Anti-doping status is the one place both are treated identically. WADA's 2026 Prohibited List names growth hormone releasing hormone and its analogues at S2.2.4, listing CJC-1293, CJC-1295, sermorelin, and tesamorelin together in a single entry. Both are prohibited at all times, in and out of competition. Accredited laboratories have published detection methods for both, including urine assays reaching low picogram-per-millilitre limits (PMID 32971474). Detecting the albumin-bound form takes a different approach, since conjugation hides it from standard peptide screening (PMID 30489688).

Regulatory status and research-use-only supply are separate matters. Research-use-only labelling states a supplier's intended use and is not a regulatory clearance, an approval, or a finding of safety. Compounding categories, anti-doping listings, and approval histories each answer different questions and should never be read as substitutes for one another.

What the research does not show

Absence of evidence is part of the evidence here. These are the gaps that genuinely exist.

No head-to-head trial has ever been published. A PubMed search for records indexing both compounds, querying cjc 1295 and sermorelin across all fields, returns 14 records in total. Every one of them is a narrative review, a doping-control assay development paper, or a class overview. Zero head-to-head trials.

No human efficacy evidence exists for muscle or body composition. An August 2026 scoping review in the American Journal of Sports Medicine examined CJC-1295 among six emerging peptides (PMID 42578445). Roughly 67% of the identified literature used preclinical animal models. Human studies were few and mostly lacked well-controlled or rigorous designs. The authors concluded that claimed musculoskeletal benefits remain unsubstantiated by current human trials.

No published human data covers the no-DAC form. Modified GRF(1-29) has no dedicated human pharmacokinetic trial anywhere in the indexed literature. That gap leaves several cells of the table above genuinely empty. Analytical work fills part of the picture for sermorelin, where doping-control researchers documented rapid degradation above 4 degrees Celsius and below pH 7 (PMID 35298973). Stability data of that kind describes handling behaviour, and it says nothing about effect in any organism.

No basis supports the combination-multiplier claims. Pages citing a specific fold-increase for GHRH analogue plus GHRP combinations are quoting figures with no primary human trial behind them. A 2026 critical review of peptide use in sport reached the same verdict across the class (PMID 41880199). Its authors noted that most published studies examine therapeutic applications under controlled conditions, and not the combined protocols discussed in forums.

When a competitor page declares a winner for fat loss or muscle gain, the useful question is which trial measured it. For these two compounds against each other, no trial did.

The research verdict

Neither compound is better than the other in any general sense. Each one answers a different research question, and that framing is the only honest one available.

Sermorelin is the closer match when the question concerns native GHRH signalling. It is the endogenous fragment itself, and its clearance pathway is characterized. It also carries genuine controlled human trial data. That data comes from a pediatric population and a different decade, which limits how far it travels.

CJC-1295 with DAC is the closer match when the question concerns sustained receptor stimulation. Among the three forms discussed here, it is the only one with published multi-day human pharmacokinetics, and its half-life was directly measured in trial subjects.

Neither compound is a match when the question concerns adult body composition. The trial evidence does not exist for either one, in either direction, and no amount of cross-study reading fills that gap.

For adjacent comparisons in this class, see sermorelin vs tesamorelin, sermorelin vs ipamorelin, and tesamorelin vs ipamorelin.